China Pharmaceuticals, Inc. Effects 1 For 3 Reverse Share Split

China Pharmaceuticals, Inc. (OTCBB: CFMID) ("China Pharmaceuticals, Inc.” or the "Company”), one of China’s leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced that it has effected a 1 for 3 reverse share split as of September 22, 2010.

China Pharmaceuticals, Inc. has officially filed amendments to its articles to the state of Nevada to affect a 1 for 3 reverse share split. The company had also filed notice of same to FINRA. The objective of the reverse share split is to better position the company for a senior stock exchange listing. "Today’s announcement further demonstrates to our shareholders that we are taking steps that we feel are necessary to position the company to attain a senior stock exchange listing,” stated Mr. Guozhu Wang, Chairman and Chief Executive Officer of China Pharmaceuticals, Inc. In conjunction with the reverse split, a temporary "D" has been added to the end of the Company’s existing trading symbol (CFMID). Typically, the "D” is automatically removed 20 days after the share split becomes effective.

About China Pharmaceuticals, Inc.

China Pharmaceuticals, Inc. www.chinapharmaceuticalsinc.com has its headquarters based in the industrial city of Xi’an, Shaanxi Province, China. The Company identifies, discovers, develops, manufactures and distributes both prescription and over-the counter pharmaceutical products, including both conventional and traditional Chinese medicines, for the treatment of some of the most common ailments and diseases. China Pharmaceuticals, Inc. currently manufactures 132 pharmaceutical products in 11 dosage forms, including capsules, oral solutions, tablets, granules, syrups, medicinal teas, tinctures and solutions for injection. The Company currently markets and distributes 111 prescription drugs representing 78% of sales distributed via 56 sales offices (including two company-owned distribution and logistics centers) to a network of hospitals and clinics nationwide. China Pharmaceuticals, Inc. operates two modern high-tech manufacturing facilities based in Hanzhong and the Xi’an Jinghe Industrial Zone, in Shaanxi Province.

For the six months period ended June 30, 2010, the Company recorded record financial results. Total revenue was $17,500,787, representing a 79% increase over the same period last year. Net income for the period was $6,015,553, representing a 69% increase over the same period last year. As at June 30, 2010, total shareholders’ equity was $36,883,263 and total assets were $40,135,508.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.